Related Experiment Video
Updated: May 18, 2026
04:46
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
Recent developments in nanotechnology-enhanced immunotherapy for glioblastoma
Davide Frumento1, Ștefan Țălu2
1Department of Education Sciences, University of Roma Tre, Rome, Italy.
Immunotherapy
|May 16, 2026
Summary
Glioblastoma immunotherapy faces challenges from the immunosuppressive tumor microenvironment and the blood-brain barrier (BBB). Nanomaterial strategies show promise for overcoming these hurdles in brain tumor treatment.
Area of Science:
- Neuro-oncology
- Immunology
- Nanomedicine
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor outcomes.
- The tumor microenvironment in GBM is highly immunosuppressive.
- The blood-brain barrier (BBB) limits drug delivery to brain tumors.
Purpose of the Study:
- To review current immunotherapies for GBM.
- To explore nanomaterial-based strategies for GBM immunotherapy.
- To highlight methods overcoming BBB and immunosuppression.
Main Methods:
- Literature search of biomedical databases.
- Focus on GBM immunotherapy and nanomaterial applications.
- Review of immune checkpoint inhibition, immune cell targeting, and immunogenic cell death.
Main Results:
- GBM's immunosuppressive microenvironment hinders immunotherapy.
- BBB impedes therapeutic agent delivery to the brain.
- Nanomaterials offer potential solutions for enhanced GBM immunotherapy.
Conclusions:
- Effective GBM immunotherapy requires BBB penetration and overcoming immunosuppression.
- Nanomaterial-based approaches are advancing GBM treatment.
- Further research into novel nanomaterial strategies is crucial.
